Foley’s National Director’s Institute and its discussion on how corporate boards can expect to deal with heightened scrutiny and heavy regulation this year are mentioned in an article titled, “Corporate Boards Should Beware: Directors Can Expect More Scrutiny Over CEO Pay From Investors, SEC, Adviser Says,” in the March 8, 2008 edition of the Milwaukee Journal Sentinel. The article also includes comments from U.S. Senator Paul Sarbanes, who served as keynote speaker at the seventh annual event.
Foley Partner Jay Rothman is also quoted in the article on the demand for public disclosure of pay and perks for top managers. Rothman comments on how companies can expect to see an enhanced focus on the executive compensation arena.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”